HK Stock Market Move | CANSINOBIO (06185) rises more than 5%, Phase I clinical trial of inhaled pulmonary tuberculosis vaccine launched in Indonesia.

CANSINOBIO (06185) rose more than 5%, up 5.03% as of the time of writing, at HK$46.38, with a turnover of HK$161.81 million. On the news front, CANSINOBIO announced that the inhaled tuberculosis vaccine (Type 5 adenovirus vector) developed by the company has recently officially started Phase I clinical trials in Indonesia, and the first subject has been included in the Phase I clinical trial. It is reported that the Phase I clinical trial is being conducted in Indonesia with the aim of investigating the safety and immunogenicity of a single dose of the inhaled tuberculosis booster vaccine in adults aged 18 to 49. In addition, Credit Suisse previously issued a research report stating that it has raised its revenue forecast for CANSINOBIO for 2026 and 2027 by 22% and lowered it by 9% respectively. The management of CANSINOBIO stated that the MCV4 vaccine contributed RMB 662 million in revenue in the first three quarters of this year, a year-on-year increase of about 28%, mainly due to the expansion of the age group and continuous penetration of channels. MCV4 has started to be exported to Indonesia in the third quarter, and the bank estimates sales of millions of RMB this year. In addition, since the launch of PCV13i in the middle of this year, it has entered approximately 12 provinces. The management's goal is to cover half of the provinces by the end of the year and expand to other markets next year.